• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

BioMarin Pharmaceutical

Boehringer Ingelheim booth at AACR 2026
Marketing

Boehringer again rises up rare disease reputation rankings

Despite back-to-back jumps, the German drugmaker failed to crack the top three of the full table, which the same three companies occupied again.
Nick Paul Taylor Aug 20, 2026 4:29am
Thumbnail from BioMarins PKU podcast

Young people with PKU take the mic in BioMarin podcast series

Jul 10, 2026 11:28am
Biomarin

Trial results set up BioMarin for expansion of Voxzogo

May 21, 2026 10:23am
reducing people on team

BioMarin lays off staffers at recently-acquired Amicus

May 12, 2026 5:12pm
Biomarin

BioMarin halts dosing, enrollment in 3 midstage Voxzogo studies

Mar 16, 2026 11:26am
Traffic light go start restart green light

FDA approves Ascendis' achondroplasia treatment Yuviwel

Mar 2, 2026 9:25am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings